SEC Tracker
Get the app

Cogent Biosciences COGT

Cogent Biosciences reports director's stock option

Karen Jean Ferrante, insider filing for COGT

Form
4
Filed
Importance
Routine
  1. Karen Jean Ferrante, director, received 759 stock options on Oct 1, 2026
  2. Options granted under non-employee director compensation plan
  3. Exercise price of $31.59, expires Oct 1, 2036

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Cogent Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  3. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  4. Geron GERN public float $861M, Jun 30, 2025
  5. CorMedix CRMD public float $910M, Jun 30, 2025